COMMUNIQUÉS West-GlobeNewswire

Summit Joins cTAP in Effort to Enhance Development of Utrophin Modulators and Other Treatments for DMD
25/09/2017
Summit Therapeutics plc ('Summit', or 'the Company') SUMMIT JOINS cTAP IN COLLABORATIVE EFFORT TO ENHANCE THE DEVELOPMENT OF UTROPHIN MODULATORS AND OTHER TREATMENTS FOR DUCHENNE MUSCULAR DYSTROPHY Oxford, UK, 25 [...]
argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis
25/09/2017
Non-regulated information September 25, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody- [...]
HomeVi announces the launch of syndication of EUR 1,020 million Senior Secured Term Loan B for debt refinancing
25/09/2017
Suresnes, September 25, 2017 - 8:30 am CET HomeVi S.A.S. ("HomeVi") today announced that it will shortly begin syndicating a Senior Secured Term Loan B of EUR 1,020 million and a Senior Secured Revolving Credit Facility [...]
Ambu A/S: Patient safety made simpler with innovative visualisation devices
25/09/2017
Integration of VivaSight further strengthens Ambu's aScope solution. In 2016, Ambu acquired Israeli company ETView and thereby the VivaSight products - single-use double-lumen and single-lumen tubes with integrated high [...]
Ambu A/S: Ambu launches 4th generation of single-use bronchoscopes
25/09/2017
Innovation: 'Ambu ® aScope TM 4 Broncho' unveiled today in Vienna at European intensive care congress. Improved image quality means that Ambu expects new scope to be relevant for 50% more hospital procedures. Over the [...]
Targovax granted US Patent for mutant-RAS neoantigen platform lead products
25/09/2017
Extends IP protection of TG01 and TG02 until 06.05.2034 Oslo, 25 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target [...]
IBA SA : IBA et Elekta signent un protocole d'entente portant sur le développement conjoint de software et de ventes pour soutenir le développement de la protonthérapie
23/09/2017
IBA et Elekta signent un protocole d'entente portant sur le développement conjoint de software et de ventes pour soutenir le développement de la protonthérapie SAN DIEGO, Etats-Unis, 23 septembre 2017 - IBA (Ion Beam [...]
IBA SA : IBA and Elekta enter an MOU regarding a comprehensive partnership including joint software development and sales to advance proton therapy treatments
23/09/2017
IBA and Elekta enter an MOU regarding a comprehensive partnership including joint software development and sales to advance proton therapy treatments SAN DIEGO, September 23, 2017 - IBA (Ion Beam Applications) and [...]
Abiomed obtient l'autorisation APMM de la FDA pour l'Impella RP® pour l'insuffisance cardiaque droite
22/09/2017
DANVERS, Massachusetts, le 22 septembre 2017 (GLOBE NEWSWIRE) - Abiomed, Inc. (NASDAQ : ABMD), fournisseur majeur de technologies innovantes d'assistance et de récupération cardiaque, a annoncé aujourd'hui qu'elle a [...]
Le portefeuille de propriété intellectuelle de Merus s'enrichit de deux nouveaux brevets grâce à sa technologie Biclonics®
22/09/2017
UTRECHT, Pays-Bas, le 20 septembre 2017 (GLOBE NEWSWIRE). -- Merus (NASDAQ : MRUS), société spécialisée en immuno-oncologie au stade clinique qui développe des traitements visant à guérir des maladies graves, a annoncé [...]
CEO Jyrki Eklund takes over the responsibilities of Aino Health Sweden AB
22/09/2017
Aino Health has progressed as planned in the internationalisation process. In the first part of this year, we have been able to develop both the Swedish and German markets. Structures are now in good shape in the [...]
Auris Medical Completes Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen® in Acute and Post-Acute Tinnitus
22/09/2017
Trial now includes more than 730 patients under previously announced amended protocol Top-line results from TACTT3 expected in first quarter 2018 Zug, Switzerland, September 22, 2017 - Auris Medical Holding AG (NASDAQ: [...]
AroCell AB: TK 210 ELISA abstract on in-vitro studies of cancer drugs has been accepted for presentation at the National Cancer Research Institute (NCRI) UK symposium
22/09/2017
AroCell AB (publ) announces today that an abstract submitted Kiran Kumar Jagarlamudi et al entitled "The AroCell TK 210 ELISA provides new information concerning the mechanism of anti-cancer drugs by determining the TK1 [...]
Affimed to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
22/09/2017
Heidelberg, Germany, September 22, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. [...]
Zealand increases its share capital as a consequence of exercise of employee warrants
22/09/2017
Company announcement - No. 46 / 2017 Zealand increases its share capital as a consequence of exercise of employee warrants Copenhagen, September 22, 2017 - Zealand has increased its share capital by a nominal amount of [...]
Solon Eiendom ASA : Primary insider notification
22/09/2017
(Oslo, Norway, 21 September 2017) Per Knut Asphaug Bernhardt, personal assistant to the chairman of the board of Solon Eiendom ASA, (through his wholly owned company Factum AS) has today acquired a forward contract with [...]
Participation de XBiotech à la conférence Global Healthcare de Cantor Fitzgerald
22/09/2017
AUSTIN, Texas, le 22 septembre 2017 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ:XBIT) a annoncé aujourd'hui la participation de sa direction à la conférence Global Healthcare de Cantor Fitzgerald qui se tiendra du 25 au 27 [...]
Orion Pharma scientists led research group wins award for study paper on dexmedetomidine oromucosal gel for noise anxiety in dogs
22/09/2017
ORION CORPORATION PRESS RELEASE 22 SEPTEMBER 2017 at 8.30 EEST Orion Pharma scientists led research group wins award for study paper on dexmedetomidine oromucosal gel for noise anxiety in dogs Orion Pharma scientists [...]
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
22/09/2017
CMLPath to Care(TM) collaboration replaces Glivec International Patient Access Program (GIPAP) with a new, independent, patient-centered access model GIPAP was introduced 15 years ago and has provided approximately 75, [...]

Pages